News

Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve fibers that is damaged in multiple sclerosis (MS), in large areas of the brain, according to a study. The tool may help assess the extent of myelin damage in…

A robotic exoskeleton dubbed Atalante X, which allows people with severe mobility issues to stand upright for rehabilitation exercises, is now cleared by the U.S. Food and Drug Administration (FDA) for use by people with multiple sclerosis (MS) and a broader range of individuals with spinal cord injuries. Additionally,…

SUDO-550, an oral TYK2 inhibitor being developed by Sudo Biosciences, was found to be safe, well-tolerated, and to fully reach the brain in a first-in-human clinical trial involving healthy volunteers, according to clinical trial results. The Phase 1 clinical trial, which began dosing late last year, also showed…

Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data from a small Phase 1 clinical trial. Researchers used Octave’s MS Disease Activity (MSDA) scale — a clinically validated test for monitoring MS disease activity — and found the majority…

People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but levels of these antibodies are not associated with disease activity or clinical worsening among MS patients. That’s according to the study, “Evaluating the role of anti-EBV antibodies…

People living with multiple sclerosis (MS) have consistently lower quality of life than the general population — regardless of age or gender, a new study shows. The scientists also identified several factors that are significantly associated with worse quality of life in MS. These included disease symptoms such as…

A third of adults live with chronic physical conditions such as multiple sclerosis (MS), but in most cases these conditions aren’t obvious to others — and many people downplay their impact to avoid making those around them uncomfortable. That’s according to a new report from Convatec, a medical…

Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for Briumvi (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (MS), developer TG Therapeutics announced. This part of the Phase 3b ENHANCE study (NCT05877963) is specifically testing whether…

Eating more carbohydrates is significantly associated with a higher risk of developing multiple sclerosis (MS), particularly among women and people younger than 60, according to a study based on data from the U.K. “Higher intakes of total carbohydrates, total sugars, fiber, fructose, and glucose were significantly associated with increased…

Metis Biotech‘s experimental oral therapy MTS-004 was safe and eased symptoms of pseudobulbar affect (PBA), a neurological condition marked by bouts of sudden, involuntary, and inappropriate laughter or crying, in people with multiple sclerosis (MS) and other neurological disorders. That’s according to data from a Phase 3 clinical…

Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis (MS) in the first three months of a clinical trial. That’s according to data from the first part…

Bionxt Solutions has launched the final animal study needed to prepare for human testing of BNT23001, its sublingual version of cladribine, in people with multiple sclerosis (MS). The 15-day dosing optimization study will compare Bionxt’s thin-film formulation with the approved tablet version of cladribine, sold as Mavenclad, in…

People with multiple sclerosis (MS) have altered levels of bacteria in their mouths, with reduced levels of normal healthy bacteria and higher levels of bacteria that can cause disease, a new study reports. “Your mouth may reveal more about your overall health than you think,” Ashutosh Mangalam, PhD, senior…

The first patient has been dosed in a Phase 1 clinical trial of Autolus Therapeutics‘ experimental CAR T-cell therapy, obecabtagene autoleucel (obe-cel), in people with progressive forms of multiple sclerosis (MS) who have failed to respond to existing treatments. Dosing took place at University College London Hospitals NHS…

Researchers have identified a protein that naturally slows myelin production — a finding that could lead to ways to repair myelin damage in multiple sclerosis (MS) and other neurological disorders. In mice, the protein (called Tfii-i) was found to limit the activity of genes that drive myelin formation. When…

Having a higher body mass index (BMI), a measure of body fat based on a person’s height and weight, at diagnosis is tied to faster disability progression in people with multiple sclerosis (MS), according to a recent study in Sweden. This effect was particularly pronounced when excess weight…

Signs of myelin damage are detectable about one year before damage to nerve fibers is apparent and about seven years before the onset of multiple sclerosis (MS) symptoms, a new study reveals. These findings shed new light on the timing of MS onset, and could open new avenues to…

A gene on the X chromosome that is more active in women than men appears to drive inflammation in the brain, helping to explain why women are more likely to develop neurological diseases such as multiple sclerosis (MS) and Alzheimer’s disease, according to a study out of the…

Liberate Bio’s CAR-M cell therapy almost completely depleted B-cells in nonhuman primates, suggesting the approach may be used to treat B-cell diseases such as multiple sclerosis (MS) and some cancers. The therapy is designed to genetically engineer monocytes and macrophages, two types of immune cells, to target and…

As a law student in the Czech Republic, Jana Hlavacova specialized in international law and international relations, but a multiple sclerosis (MS) diagnosis led her to shift her professional focus. Applying her legal expertise to her work at the Czechia Ministry of Health, she now helps shape healthcare policy…

Abnormal brain cells, known as disease-associated radial glia or DARGs, may play a key role in driving chronic inflammation in people with progressive forms of multiple sclerosis (MS), a new study shows. Based on the finding, researchers are now working to better understand the biology of DARGs, with an…

When Jill Blackburn’s daughter, Sierra, was diagnosed with pediatric multiple sclerosis (MS) at the age of 15, Blackburn had trouble finding sufficient support and resources. She eventually joined a relevant Facebook group, which she evolved into a nonprofit organization, the Pediatric Multiple Sclerosis Alliance. She now serves as…

People with multiple sclerosis (MS) are more than twice as likely to experience headaches, including migraines, than their healthy counterparts, a study from Greece found. Headaches were also longer and more intense for MS patients, and more likely to lead to the use of acute medication. “These findings suggest that headaches…

The U.S. Food and Drug Administration (FDA) has given Tr1x the green light to launch a first-in-human clinical trial of TRX319, a cell therapy candidate designed to restore immune balance in people with progressive forms of multiple sclerosis (MS). With FDA clearance now granted for its investigational new…

The U.S. Food and Drug Administration (FDA) granted fast track designation to EG110A, EG 427‘s DNA-based therapy to treat neurogenic detrusor overactivity (NDO) — a bladder disorder that can arise from spinal cord injury or neurodegenerative conditions such as multiple sclerosis (MS). The FDA gives fast track status to experimental…

Going through menopause with multiple sclerosis (MS) can be challenging, as the changes that come with this stage of life may interact or occur in tandem with existing MS symptoms. A team of researchers recently studied how menopause affects women living with MS, with their findings presented…

Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules, implying that targeting these molecules may be a viable strategy to treat MS-related seizures, according to new research done in a mouse model. “If the same transporters and receptors are…

Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers. The funds come from the Advanced Research Projects Agency for Health’s (ARPA-H) EMBODY program, which aims to support the…

Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two compounds have shown promise in cell and animal models, and preclinical work is ongoing to bring them into clinical testing. The compounds were identified by academic researchers, but the program…

A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood test for detecting disease progression in people with multiple sclerosis (MS). The company is developing its MS Disease Progression test, or MSDP, to objectively measure MS progression based on…